In this interview, Frank Gleeson, co-founder and CEO of Satellos Bioscience, discusses the company’s pioneering approach to muscle regeneration. Satellos is leading the exploration of a novel mechanism called muscle stem cell polarity, which could revolutionise treatments for degenerative muscle conditions like DMD. Gleeson also highlights the potential of their lead drug SAT-3247, offering new hope for those affected by this debilitating disease.
Click here to read the article in this report on advances in stem cell research by Drug Target Review.
